2 results
Approved WMOCompleted
PrimaryTo evaluate confirmed ORR of Trastuzumab deruxtecan in human epidermal growth factor receptor 2- (HER2-) mutated NSCLC subjects treated at 5.4 and 6.4 mg/kg doses.Secundary- To evaluate the clinical efficacy of Trastuzumab deruxtecan at 5.4…
Approved WMOCompleted
The primary objective of this study is to assess the patient*s experience of performing home BP measurements themselves (feasibility) in the first month after carotid endarterectomy. Furthermore, the secondary objective will be the time from the…